MODD VS MRKR Stock Comparison

PerformanceTechnicalsEarningsProfitVolatility
PerformanceTechnicalsEarningsProfitVolatility

Performance

MODD
10/100

MODD returned -66.69% in the last 12 months. Based on SPY's performance of -13.85%, its performance is below average giving it a score of 10 of 100.

MRKR
10/100

MRKR returned -20.79% in the last 12 months. Based on SPY's performance of -13.80%, its performance is below average giving it a score of 10 of 100.

Technicals

MODD
29/100

MODD receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

MRKR
21/100

MRKR receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

MODD
21/100

MODD has missed earnings 3 times in the last 20 quarters.

MRKR
10/100

MRKR has missed earnings 6 times in the last 20 quarters.

Profit

MODD
10/100

Out of the last 20 quarters, MODD has had 0 profitable quarters and has increased their profits year over year on 0 of them.

MRKR
10/100

Out of the last 20 quarters, MRKR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

MODD
41/100

MODD has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

MRKR
58/100

MRKR has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Modular Medical, Inc. Common Stock Summary

Nasdaq / MODD
Healthcare
Medical - Devices
Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.

Marker Therapeutics, Inc. Common Stock Summary

Nasdaq / MRKR
Healthcare
Biotechnology
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.